Respirology | Home | MIMS Malaysia

Respirology

Inflammatory indices help gauge efficacy of atezolizumab against NSCLC

Yesterday

Inflammatory indices, such as the neutrophil-to-lymphocyte (NLR) and lymphocyte-to-monocyte (LMR) ratios, may help determine the efficacy of atezolizumab monotherapy in patients with nonsmall cell lung cancer (NSCLC), a recent study has found.

Flu shot during pregnancy not tied to autism in offspring

Pearl Toh, 2 days ago

Having vaccination against influenza during pregnancy was not associated with an increased risk of autism spectrum disorder (ASD) in the offspring, a large cohort study reveals — providing more support for vaccination during pregnancy.

Laryngeal tube tied to worse placement success, complications in OHCA

Stephen Padilla, 2 days ago

Use of the laryngeal tube (LT) for out-of-hospital cardiac arrest (OHCA) by paramedics in Singapore leads to poorer placement success and more complications as compared with laryngeal mask airway (LMA), a study has found.

Selpercatinib may alter the landscape of RET-altered cancers

Audrey Abella, 2 days ago

The novel, next-generation, highly potent and selective RET inhibitor selpercatinib may modify the landscape of another genomic subgroup — RET-altered cancers, according to two early-phase trials investigating the potential of selpercatinib in medullary thyroid cancer (MTC) and non-small-cell lung cancer (NSCLC).

Age, comorbidities may be to blame for higher COVID-19 mortality in cancer patients

Roshini Claire Anthony, 5 days ago

The increased risk of mortality among patients with cancer diagnosed with COVID-19 may be due to their older age and presence of comorbidities, according to a study presented at ECCVID 2020.

Mepolizumab: Targeting eosinophils in severe asthma with precision medicine

Pearl Toh, 16 Sep 2020

Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.

Expert consensus: Patient profile should guide antihistamine choice in primary care setting

10 Dec 2019

Oral H₁-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.

Clarithromycin: Beyond its role as an antibiotic

01 Dec 2019

Macrolide antibiotics are derived from the Streptomycesspecies. These contain either 14-membered (erythromycin [ERM],clarithromycin [CAM], roxithromycin [RXM]), 15-membered(azithromycin [AZM]) or 16-membered (spiramycin, josamycin,midecamycin) macrocyclic lactone rings. They inhibit proteinsynthesis by reversibly binding to the 23S ribosomal RNA (rRNA)in the 50s subunit of the bacterial ribosome. Traditionally,macrolides are used as first-line agents in respiratory, skin,soft tissue, and urogenital infections, and they are also activeagainst gram-positive cocci and atypical pathogens.

Pneumonia prevention through nationwide adult immunisation

01 Dec 2019

Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.

Antihistamine therapy for allergic rhinitis and urticaria: An Asia-Pacific perspective

01 Nov 2018

The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.

Optimizing hypertension management in clinical practice with nebivolol

Prof. Giuseppe Mancia, Prof. Jong-Won Ha, Prof. Lin Jiunn-Lee, 11 Jul 2018

Hypertension guidelines diﬀer in their recommendation to use beta-blockers as ﬁrst-line agents. At a Menarini-sponsored symposium held during the Asian Paciﬁc Society of Cardiology Congress 2018 in Taipei, Taiwan, Professor Giuseppe Mancia from the University of Milano-Bicocca in Milan, Italy and Professor Jong-Won Ha from the Yonsei University College of Medicine in Seoul, Korea discussed the rationale behind these recommendations, and reviewed the role of beta-blockers in hypertension management, particularly the role of vasodilatory beta-blocker nebivolol (Nebilet^®, Menarini). Professor Lin Jiunn-Lee, APSC 2018 chairman and president of the Taiwan Society of Cardiology, chaired the symposium.

Age, comorbidities may be to blame for higher COVID-19 mortality in cancer patients

Roshini Claire Anthony, 20 Oct 2020

The increased risk of mortality among patients with cancer diagnosed with COVID-19 may be due to their older age and presence of comorbidities, according to a study presented at ECCVID 2020.

Which COVID-19 serological assays to choose?

Pearl Toh, 17 Oct 2020

A head-to-head study comparing five serological assays for SARS-CoV-2 antibodies showed that a commercial immunoassay by Siemens and a novel ELISA* test developed by the University of Oxford could achieve the desired sensitivity and specificity without further optimization — providing reassurance for their use.

Stopping long-term mepolizumab may lead to exacerbations, loss of asthma control

Roshini Claire Anthony, 07 Oct 2020

In patients with severe eosinophilic asthma, cessation of mepolizumab may lead to increased exacerbations and reductions in asthma control, according to results of the COMET* trial.

40% of HCWs with COVID-19 are asymptomatic, risk silent transmission

Pearl Toh, 05 Oct 2020

As high as 40 percent of the healthcare workers (HCWs) infected with COVID-19 were asymptomatic, raising concerns on silent transmission in the healthcare settings, according to a systematic review and meta-analysis released during ECCVID 2020.

Amoxicillin-clavulanate regimen for PBB: 4 weeks no better than 2 weeks

Roshini Claire Anthony, 28 Sep 2020

A 4-week course of amoxicillin-clavulanate in children with protracted bacterial bronchitis (PBB) does not improve cough resolution rates compared with a 2-week course, according to a study from Australia. However, the longer course may significantly extend time to first cough exacerbation.

Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!